RTsafe and TheraPanacea join hands towards supporting an AI-based research and clinical trial project aiming to improve survival of brain tumor patients through personalized radiation treatment.

11January 2021

Athens, Greece – Paris, France 11 January 2021

TheraPanacea, Institut Gustave Roussy, AP-HP Pitié Salpétrière, Institut de Cancérologie Strasbourg Europe, and GE-Healthcare recently announced a promising collaboration to provide an AI-powered solution to optimize the response to radiation treatment of patients with brain tumors (glioblastoma) via a personalized treatment approach (link to the announcement).

Leveraging on its expertise in developing cutting-edge, AI-powered software* to optimize diagnostics, prognostics, and therapies for cancer, TheraPanacea will develop an AI, radiomics-based algorithm to shed light on the complex structure of GBM and unlock underlying local characteristics that are invisible to human eyes.

To enable the crucial spatial and dosimetric accuracy of the treatment dose deposition, the consortium will combine these powerful AI solutions with domain knowledge coming from renowned clinical institutions.

RTsafe’s involvement in this project, will aim to a) create an End-to-End quality assurance framework to assure the essential harmonized and standardized best practice dose delivery process among the clinical institutions participating in the project b) provide the required common auditing platform to an optimally designed clinical trial and c) support with personalized quality assurance the radiotherapy treatments of the patients participating in the clinical trial. The latter will be achieved using the  PseudoPatient®** solution, the unique RTsafe’s approach for personalizing patient safety and treatment verification.


“Local dose delivery and control are the pillars towards implementing this ambitious clinical treatment paradigm shift regarding glioblastoma tumors. The RTsafe solution – a world-wide innovative clinical device – offers the only effective avenue for the successful implementation of this effort towards guaranteeing patient security and optimal outcomes. This cooperation goes beyond the scope of glioblastoma tumors and is fully aligned with our ambitious strategic objective of treatment adaption on the fly. RTsafe solutions pave the way for demonstrating the necessity of this pivotal action in radiation oncology.” states Professor Nikos Paragios, CEO of TheraPanacea.


“The consortium built by TheraPanacea, some of the leading French radiotherapy institutions and GE Healthcare aims to develop an individualized efficient and safe treatment of GBM, empowered by AI. RTsafe is truly delighted to be part of such a promising project via its direct collaboration with TheraPanacea, the global leader of AI driven solutions in radiation oncology. Our vision for a continuous improvement of radiotherapy efficiency and patient safety via the use of our patented technology for personalized quality assurance, completely matches with the project milestones. Our collaboration with TheraPanacea, going beyond the needs of the current project, aims to develop and enable clinically a standardized process for personalized RT, via a superposition of the TheraPanacea’s AI software personalized solutions and RTsafe’s experimental personalized quality assurance methodologies.” said Professor Evangelos Pappas, Founder and CSO of RTsafe.


* ART-Plan™, TheraPanacea’s first software product for radiotherapy, has been available on the European market since 2019.

** PseudoPatient® phantoms are available in the European and USA markets (510k-FDA cleared) since 2018


Press to download the Press Release


About TheraPanacea: A medical technology company created in 2017, TheraPanacea develops top-notch software for smarter cancer diagnosis, prognosis, and treatment. TheraPanacea’s first software for radiotherapy, ART-Plan ™, has been available on the European market since 2019. Since its creation, TheraPanacea has won prestigious distinctions and prizes including the European Research Council (ERC) Proof of Concept Grant (2016), the Digital Innovation Competition (Bpifrance), the Grands Prix d’Innovation de la Ville de Paris in Health category (2017), the 1st AI Challenge prize for the Paris region (2018) and the H2020 – SME Instrument Phase 2 prize (2019) rewarding the most disruptive European companies in their market.

For media inquiries, please contact Ms. Catherine Huynh  | +33 6 47 93 51 65 | [email protected]


About RTsafe: RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. It combines proven expertise in medical physics with highly accurate 3D printing technology to create anatomically accurate effigies enabling medical professionals to simulate treatment and plan more precise treatment interventions for each patient and help radiotherapy technology innovators to fine‐tune their products. The result is a more effective therapy and reduced patient risk.

For media inquiries, please contact Ms. Marianna Liondou | +30 6944 360 641 | [email protected]


Explore our Products
& Services
  • 11April 2024

    RTsafe to exhibit at ISRS Congress 2024 in New York, USA

    Read More
  • 03April 2024

    RTsafe and the Spanish Radiosurgery Society (SER) signed a strategic partnership agreement towards optimizing Stereotactic Radiosurgery treatment quality in Spain 

    Read More

Request a quote

ΕΣΠΑ Banner